Novel and emerging therapies for pulmonary hypertension

Area of Science:

• Cardiovascular Research
• Pulmonary Medicine
• Molecular Biology

Background:

• Pulmonary hypertension (PH) pathogenesis involves complex molecular and cellular sequelae.
• Understanding vasomotion and vascular remodeling is crucial for developing effective PH therapies.
• Current knowledge gaps exist in the molecular pathways driving diverse vascular phenotypes in PH.

Purpose of the Study:

• To highlight advances in understanding PH pathogenesis and novel therapeutic strategies.
• To review progress in identifying cellular and molecular mechanisms for PH treatment.
• To emphasize the need for research into PH groups 2-5.

Main Methods:

• Perspective review of recent research in PH.
• Analysis of molecular signaling, cellular abnormalities, and vascular remodeling in PH.
• Exploration of novel therapeutic concepts including reverse-remodeling, regenerative strategies, and targeted therapies.

Main Results:

• Advances in understanding redox-dependent signaling, inflammation, metabolic abnormalities, and hyperproliferation in PH.
• Identification of novel therapeutic concepts such as antiproliferative strategies, transcription factor-based therapies, and epigenetic modulation.
• Exploration of regenerative strategies using genetically engineered stem cells for PH.

Conclusions:

• Therapeutic development for PH is advancing through a deeper understanding of its pathogenesis.
• Novel treatment concepts like reverse-remodeling and regenerative medicine show promise for PH.
• Further research is urgently needed to understand and treat PH across all its groups, particularly groups 2-5.